Shares of MACK stock traded up $0.04 during mid-day trading on Monday, reaching $6.12. 1,682 shares of the company’s stock traded hands, compared to its average volume of 102,092. The company has a debt-to-equity ratio of 0.25, a current ratio of 5.14 and a quick ratio of 5.14. Merrimack Pharmaceuticals has a 12 month low of $3.34 and a 12 month high of $10.53.
Merrimack Pharmaceuticals (NASDAQ:MACK) last released its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.04.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in shares of Merrimack Pharmaceuticals during the 4th quarter valued at about $70,000. D. E. Shaw & Co. Inc. grew its holdings in Merrimack Pharmaceuticals by 78.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 55,124 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 24,173 shares during the last quarter. Northern Trust Corp grew its stake in Merrimack Pharmaceuticals by 20.5% in the 4th quarter. Northern Trust Corp now owns 60,417 shares of the biopharmaceutical company’s stock worth $233,000 after acquiring an additional 10,263 shares in the last quarter. Two Sigma Investments LP grew its stake in Merrimack Pharmaceuticals by 28.7% in the 4th quarter. Two Sigma Investments LP now owns 72,877 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 16,254 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Merrimack Pharmaceuticals by 54,994.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 55,094 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 54,994 shares in the last quarter. Hedge funds and other institutional investors own 46.20% of the company’s stock.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
See Also: Terms to Better Understand Call Options
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.